Crizotinib

Evidence Level: L5

Predicted Indications: 9

Crizotinib

Pharmacist Assessment Report

Crizotinib: ALK/ROS1/MET tyrosine kinase inhibitor → Gingival fibromatosis (fibromatosis, gingival)

One-Sentence Summary

Crizotinib is an oral kinase inhibitor that blocks ALK, ROS1 and MET. The TxGNN model predicts it may be relevant to gingival fibromatosis (fibromatosis, gingival), but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Gingival fibromatosis (fibromatosis, gingival)
TxGNN Prediction Score	0.9981
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Crizotinib inhibits the receptor tyrosine kinases ALK, ROS1 and MET. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the drug’s generally known targets.

No pathway has been shown that connects these targets to gingival fibromatosis, a condition of gum tissue overgrowth. The high TxGNN score (0.9981) is a computational output only. The analysis found no identified mechanistic link, and no similarity analysis with the drug’s current use has been completed.

The prediction should therefore be treated as a hypothesis for screening, not as a supported repurposing direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
48989	Crizalk 250mg Capsule	Box of 60 capsules	Not recorded
48988	Crizalk 200mg Capsule	Box of 60 capsules	Not recorded

Both registrations are single-ingredient products from Pfizer Ltd and both are currently valid.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert; liver function and cardiac monitoring are generally advised for this class
Handling Protection	Please refer to the package insert and local cytotoxic drug handling rules

Safety Considerations

Drug Interactions: 566 interactions were identified in total. Major-level examples include clarithromycin, cisapride, dolasetron, eliglustat and granisetron. Moderate-level examples include famotidine, metformin, loperamide, bupropion, aprepitant and dexamethasone.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a very high model score but no clinical trials, no literature and no identified mechanistic link, so the evidence level is L5. There is no basis yet to move toward development.

To proceed, the following is needed:

Preclinical or mechanistic evidence linking ALK, ROS1 or MET signalling to gingival fibromatosis
Detailed mechanism-of-action data for crizotinib
Package insert warnings and contraindications from the local regulator
A route and formulation assessment, since the available product is an oral capsule
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.